Etelcalcetide is a calcium-sensing receptor agonist for the treatment of secondary hyperparathyroidism for patients with chronic kidney disease (CKD) on hemodialysis. Etelcalcetide is administered intravenously at the end of each dialysis session. It functions by binding to and activating the calcium-sensing receptor (CaSR) in the parathyroid gland as an allosteric activator, resulting in PTH reduction and suppression. Elevated PTH is often observe in patients with CKD. AMG 416 is in clinic trials for the treatment of secondary hyperparathyroidism in hemodialysis patients.
Cui, Sheng; Ranganathan, Krishnakumar; Crockett, Richard; Chen, Ying; Swietlow, Aleksander; Crossley, Kevin; Shi, Yun; Decroos, Karel; Moniotte, Etienne. Solution phase method for preparing etelcalcetide. WO 2016154580. (Assignee Amgen Inc., USA)
Xue, Hongxiang; Pan, Junzhu; Yang, Yanping; Kang, Yanping; Li, Changbing; Tuo, Shichuan; Wang, Lichun; Wang, Jingyi. Preparation of velcalcetide by solid phase peptide synthesis method. CN 108218957. (Assignee Sichuan Kelun Pharmaceutical Research Co., Ltd., Peop. Rep. China)
Chen, Yonghan; Mi, Pengcheng; Tao, Anjin; Yuan, Jiancheng. Method for synthesizing etelcalcetide. Assignee Hybio Pharmaceutical Co., Ltd., Peop. Rep. China. WO 2017114240. 2017.
